Oesophagogastric junction adenocarcinoma: Which therapeutic approach?

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 296-305

  Mariette, Christophe ^a,b   Piessen, Guillaume ^a,b   Briez, Nicolas ^a   Gronnier, Caroline ^a   Triboulet, Jean Pierre ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN;

BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CHEMORADIOTHERAPY; DEVELOPED COUNTRY; DRUG EFFICACY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SURGERY; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTRECTOMY; HIGH RISK PATIENT; HUMAN; LAPAROSCOPIC SURGERY; LAPAROTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL DECISION MAKING; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PREOPERATIVE TREATMENT; PREVALENCE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; STOMACH CANCER; SURGICAL APPROACH; THORACOTOMY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; STOMACH NEOPLASMS;

EID: 79952039238     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70125-X     Document Type: Review

References (65)

1. Devesa SS, Blot WJ, Fraumeni JF Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
2. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001, 92:549-555.
3. Siewert JR, Feith M, Werner M, Stein HJ Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients. Ann Surg 2000, 232:353-361.
4. Peracchia A, Bonavina L Outcome of surgical treatment. Adenocarcinoma of the esophagogastric junction 2000, 151-169. EDRA, Milan. A. Perrachia, L. Bonavina (Eds.).
5. Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg 2002, 89:1156-1163.
6. Fein M, Fuchs KH, Ritter MP, et al. Application of the new classification for cancer of the cardia. Surgery 1998, 124:707-713.
7. Sauvanet A, Mariette C, Triboulet JP Cancer du cardia. Rapport de l'AFC 2003 2003, 73-109. Ed Arnette.
8. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008, 57:1200-1206.
9. Pech O, May A, Rabenstein T, Ell C Endoscopic resection of early oesophageal cancer. Gut 2007, 56:1625-1634.
10. DeMeester SR Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006, 13:12-30.
11. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009, 360:2277-2288.
12. Pouw RE, Bergman JJ Endoscopic resection of early oesophageal and gastric neoplasia. Best Pract Res Clin Gastroenterol 2008, 22:929-943.
13. Manner H, May A, Pech O, et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008, 103:2589-2597.
14. Hölscher AH, Drebber U, Mönig SP, Schulte C, Vallböhmer D, Bollschweiler E Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. Ann Surg 2009, 250:791-797.
15. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719-3725.
16. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733. Medical Research Council Oesophageal Cancer Working Group.
17. Feith M, Stein HJ, Siewert JR Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006, 15:751-764.
18. Hermanek P pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J Surg 1995, 19:184-190.
19. Mariette C, Piessen G, Triboulet JP Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007, 8:545-553.
20. Triboulet JP Chirurgie du tube digestif haut 2010, Elsevier Masson SAS, Paris, France.
21. Benchimol D, Karimdjee-Soilihi B Oesogastrectomie par voie abdominale et thoracique droite. Opération de Lewis-Santy. J Chir Viscérale 2002, 139:150-155.
22. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006, 7:644-651.
23. Wu PC, Posner MC The role of surgery in the management of oesophageal cancer. Lancet Oncol 2003, 4:481-488.
24. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662-1669.
25. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007, 246:992-1000.
26. Sauvanet A, Mariette C, Thomas P, et al. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg 2005, 201:253-262.
27. Songun I, Putter H, Meershoek-Klein Kranengarg E, Van de velde CJH. 15-years follow-up results of the randomized D1-D2 trial: lower cancer-related mortality after D2. European Cancer Conference-European Society of Medical Oncology Meeting; Berlin, Germany; Sept 20-24, 2009. Abstract 46LBA.
28. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008, 359:453-462.
29. Martin RC, Jaques DP, Brennan MF, Karpeh M Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002, 236:159-165.
30. Gemmill EH, McCulloch P Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg 2007, 94:1461-1467.
31. Mariette C Open versus laparoscopically-assisted esophagectomy for cancer (accessed Jan 6, 2010). http://clinicaltrials.gov/ct2/show/NCT00937456.
32. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999, 230:170-178.
33. Falcone A Future strategies and adjuvant treatment of gastric cancer. Ann Oncol 2003, 14:ii45-ii47.
34. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
35. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 2007, 18:1354-1358.
36. Sun P, Xiang JB, Chen ZY Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009, 96:26-33.
37. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979-1984.
38. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067.
39. Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004, 30:643-649.
40. Songun I, Keizer HJ, Hermans J, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999, 35:558-562.
41. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
42. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol 2007, 25. abstr 4510.
43. Thirion PG, Michiels S, Le Maître A, Tierney J Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. Proc Am Soc Clin Oncol 2007, 25. on behalf of the Metaanalysis of Chemotherapy in Esophagus Cancer Collaborative Group, abstr 4512.
44. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226-234. for the Australasian Gastro-Intestinal Trials Group.
45. Lordick F, Ott K, Krause B-J, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8:797-805.
46. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
47. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
48. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659-668. for the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG).
49. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
50. Thirion PG, Maillard E, Pignon J Individual patient data-based meta-analysis assessing the effect of preoperative chemo-radiotherapy in resectable oesophageal carcinoma. Int J Radiat Oncol Biol Phys 2008, 72:S71-S72. Group 2 M.A. of Chemo in Oesophagus Cancer Collaborative Group.
51. Gaast AV, Van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. Proc Am Soc Clin Oncol 2010, 28. abstr 4004.
52. Mariette C, Seitz JF, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD9901. Proc Am Soc Clin Oncol 2010, 28. abstr 4005.
53. Hallissey MT, Dunn JA, Ward LC, Allum WH The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994, 343:1309-1312. for the British Stomach Cancer Group.
54. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
55. Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). Proc Am Soc Clin Oncol 2009, 27. abstr 4515.
56. Park SH, Kim DY, Heo JS, et al. Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 2003, 14:1373-1377.
57. Randomized phase III trial of adjuvant chemotherapy or chemoradiotherapy in resectable gastric cancer (CRITICS) Dutch Colorectal Cancer Group, (accessed April 4, 2010). http://clinicaltrials.gov/ct2/show/NCT00407186.
58. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851-856.
59. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
60. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
61. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593-1598.
62. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007, 14:2702-2713.
63. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
64. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008, 19:1450-1457.
65. Cunningham D Combination chemotherapy with or without bevacizumab in treating patients with previously untreated stomach cancer or gastroesophageal junction cancer that can be removed by surgery. NCT00450203 (accessed Jan 24, 2010). http://clinicaltrials.gov/ct2/show/NCT00450203.